Investor Relations

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID^®, VIDAZA^®, THALOMID^®, POMALYST^®/IMNOVID^®, ABRAXANE^®, OTEZLA^®, ISTODAX^® and IDHIFA^®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs^® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.